DFV-890 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval

DFV-890 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Jun 18, 2024 - 04:00

DFV-890 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Read the original article

Tags:

Previous Article

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: White House moves closer to a ban on menthol cigarettes, amid intensifying opposition from tobacco companies

STAT+: White House moves closer to a ban on menthol cig...

Oct 16, 2023

When young people survive cancer, their mental-health struggles are often just beginning

When young people survive cancer, their mental-health s...

Jun 28, 2023

STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more

STAT+: Pharmalittle: We’re reading about a failed schiz...

Mar 13, 2024